Drugs / BMS-984923
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06632990 | Nov 2024 → Apr 2025 overdue | — | Allyx Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05804383 | Mar 2023 → Jul 2025 | Alzheimer disease | Allyx Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04805983 | Mar 2021 → Apr 2022 | Alzheimer disease | Yale University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05817643 Comparator | Jan → Feb 2023 | Alzheimer disease | Allyx Therapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-984923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05804383 ↗ |
| Modality | Small molecule | — CHEMBL4571075 ↗ |
| Route | Oral | “Oral capsule” NCT05817643 ↗ |